demcizumab

Home
Ligands
demcizumab

GtoPdb Ligand ID: 8451

Synonyms: OMP-21M18 | OMP21M18

Comment: Demcizumab is a humanised IgG2 monoclonal antibody targeting DLL4 (delta like canonical Notch ligand 4), a membrane bound Notch receptor ligand expressed predominantly on vascular endothelial cells.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. A BLAST search using the peptide sequence of the variable region of the heavy chain forming demcizumab reveals US7750124 B2 as the covering patent [2].

References
1. Coleman RL, Handley KF, Burger R, Molin GZD, Stagg R, Sood AK, Moore KN. (2020) Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. Gynecol Oncol, 157 (2): 386-391. [PMID:32037195]
2. Gurney A, Axelrod F, Hoey T, Satyal S. (2010) Anti-human DLL4 antibodies and compositions. Patent number: US7750124 B2. Assignee: Oncomed Pharmaceuticals, Inc.. Priority date: 29/09/2006. Publication date: 06/07/2010.
3. McKeage MJ, Kotasek D, Markman B, Hidalgo M, Millward MJ, Jameson MB, Harris DL, Stagg RJ, Kapoun AM, Xu L et al.. (2018) Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC. Target Oncol, 13 (1): 89-98. [PMID:29188408]

References

1. Coleman RL, Handley KF, Burger R, Molin GZD, Stagg R, Sood AK, Moore KN. (2020)
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Gynecol Oncol, 157 (2): 386-391. [PMID:32037195]

2. Gurney A, Axelrod F, Hoey T, Satyal S. (2010)
Anti-human DLL4 antibodies and compositions.
Patent number: US7750124 B2. Assignee: Oncomed Pharmaceuticals, Inc.. Priority date: 29/09/2006. Publication date: 06/07/2010.

3. McKeage MJ, Kotasek D, Markman B, Hidalgo M, Millward MJ, Jameson MB, Harris DL, Stagg RJ, Kapoun AM, Xu L et al.. (2018)
Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.
Target Oncol, 13 (1): 89-98. [PMID:29188408]